US Markets

Deciphera Pharma's late-stage stomach cancer study meets main goal

Deciphera Pharmaceuticals Inc said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc DCPH.O said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

The study tested the treatment, ripretinib, in 129 patients with advanced gastrointestinal stromal tumors.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)

((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More